Rubius Therapeutics, Inc. (NASDAQ:RUBY – Get Rating) was the recipient of a significant increase in short interest in February. As of February 28th, there was short interest totalling 2,800,000 shares, an increase of 83.0% from the February 13th total of 1,530,000 shares. Currently, 6.1% of the company's stock are short sold. Based on an average trading volume of 4,100,000 shares, the days-to-cover ratio is currently 0.7 days.
Institutional Investors Weigh In On Rubius Therapeutics
Several institutional investors have recently bought and sold shares of RUBY. Renaissance Technologies LLC grew its holdings in Rubius Therapeutics by 617.0% during the second quarter. Renaissance Technologies LLC now owns 826,458 shares of the company's stock worth $703,000 after buying an additional 711,190 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Rubius Therapeutics in the 3rd quarter valued at $236,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in Rubius Therapeutics by 521.5% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 353,813 shares of the company's stock valued at $301,000 after purchasing an additional 296,886 shares during the period. AQR Capital Management LLC bought a new position in Rubius Therapeutics in the 2nd quarter valued at $140,000. Finally, BlackRock Inc. grew its stake in Rubius Therapeutics by 11.3% in the 3rd quarter. BlackRock Inc. now owns 1,587,927 shares of the company's stock valued at $688,000 after purchasing an additional 161,695 shares during the period. Institutional investors own 76.11% of the company's stock.
Get Rubius Therapeutics alerts:Rubius Therapeutics Trading Down 26.8 %
Rubius Therapeutics stock traded down $0.01 during trading on Friday, hitting $0.04. 1,397,974 shares of the company were exchanged, compared to its average volume of 9,594,584. The business's 50 day moving average is $0.20 and its 200 day moving average is $0.33. Rubius Therapeutics has a 52 week low of $0.03 and a 52 week high of $6.18.
About Rubius Therapeutics
(Get Rating)
Rubius Therapeutics, Inc engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Foxboro, MA.
Featured Stories
- Get a free copy of the StockNews.com research report on Rubius Therapeutics (RUBY)
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
